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Abstract
Development of streptomycin resistance in Mycobacterium tuberculosis is usually associated with mutations in rpsL and rrs genes, although up
to 50% of clinical streptomycin-resistant isolates may present no mutation in either of these genes. In the present report we investigate the
role of gidB gene mutations in streptomycin resistance. We have analyzed 52 streptomycin-resistant and 30 streptomycin-susceptible
Mycobacterium tuberculosis clinical isolates by sequencing and endonuclease analysis of the gidB and rpsL genes. All clinical isolates were
genotyped by 12-loci MIRU-VNTR. The gidB gene of 18 streptomycin-resistant isolates was sequenced and four missense mutations were
found: F12L (1/18), L16R (18/18), A80P (4/18) and S100F (18/18). The remaining isolates were screened by endonuclease analysis for
mutations A80P in the gidB gene and K43R in the rpsL gene. Overall, mutation A80P in the gidB gene was found in eight streptomycin-
resistant isolates and 11 streptomycin-susceptible multidrug-resistant isolates. Also noteworthy, is the fact that gidB mutations were only
present in isolates without rpsL and rrs mutations, all from genetic cluster Q1. Streptomycin quantitative drug susceptibility testing showed
that isolates carrying the gidB A80P mutation were streptomycin intermediate-level resistant and that standard drug susceptibility testing
yielded inconsistent results, probably due to borderline resistance. We conclude that gidB mutations may explain the high number of
streptomycin-resistant strains with no mutation in rpsL or rrs. These mutations might occasionally confer low-level streptomycin resistance
that will go undetected in standard susceptibility testing.
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Introduction
Streptomycin is an aminoglycoside antibiotic, the ﬁrst that
was introduced in the treatment of tuberculosis (TB),
revolutionizing the treatment of this disease. Although
mostly regarded as a tuberculostatic agent, streptomycin is
no longer a ﬁrst option in standardized TB treatments for
new cases. It is still incorporated in ﬁrst-line therapeutic
regimens for TB in patients who have previously been
treated for TB (former World Health Organization, WHO,
Category II ‘‘retreatment’’ regimen). In some countries it is
incorporated in second-line regimens for drug-resistant TB,
although it’s not the ﬁrst choice for injectable aminoglyco-
sides given the high rates of streptomycin resistance in drug-
resistant TB [1,2].
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In spite of this, due to the global emergence of resistant
Mycobacterium tuberculosis (M. tuberculosis) strains, such as
multidrug-resistant (MDR) and extensively drug-resistant
(XDR) strains, streptomycin may regain an important role in
the management of TB.
Portugal has an intermediate incidence rate when compared
with other countries of the European Union, with 2398 new
cases (22.5 new cases per 100 000 habitants) in 2010, but a
worrying situation regarding M/XDR-TB [3–7]. The latest TB
surveillance data available and published by the European
Centre for Disease Prevention and Control for streptomycin
resistance reported, in 2008, a 9.5% prevalence of streptomy-
cin resistance (156 cases out of 1641 cases with DST results),
which exceeded other drug resistance prevalences, such as
that of isoniazid (7.4%) and rifampicin (1.8%) [8].
Streptomycin inhibits protein synthesis through irreversible
binding to the A-site of the 30S ribosomal subunit and to the
ribosomal protein S12. Ribosomes bound to streptomycin are
unable to initiate and elongate during the process of gene
translation. Streptomycin also prevents dissociation of ribo-
somal 50S and 30S subunits [9,10].
Accordingly, with its mode of action, streptomycin resis-
tance is usually mediated by mutations in the rpsL and rrs genes,
which encode the ribosomal protein S12 and the 16S rRNA,
respectively [9]. The most common mutation occurs in codon
43 of the rpsL gene and can be detected by PCR-restriction
fragment length polymorphism (RFLP) with MboII [11]. Muta-
tions conferring streptomycin resistance in rrs have also been
described, usually in the 530 and 912 loop regions, and because
M. tuberculosis only possesses one copy of the rRNA operon,
one mutation in this gene is enough to cause resistance [9,12].
More recently, a new gene, gidB, encoding an rRNA methyl-
transferase was implicated in streptomycin resistance [13].
The gene product of gidB is involved in the methylation of 16S
rRNA, more speciﬁcally at position G527. As binding of
streptomycin to 16S rRNA is crucial to its action mechanism,
mutations in gidB may well be responsible and explain
streptomycin resistance when no mutation is found on rpsL
or rrs [13]. Notably, in the streptomycin-resistant strains
isolated in our laboratory, rrs mutations that confer strepto-
mycin resistance were never detected in the streptomycin-
resistant strains lacking rpsL mutations [3].
The gidB gene is highly conserved in all eubacteria, including
Mycoplasma genitalium, and loss of function has been implicated
in high-level streptomycin resistance in Salmonella but with
low-level resistance in M. tuberculosis [14,15].
In this study, we screened 52 streptomycin-resistant and 30
streptomycin-susceptible isolates circulating in the Lisbon
Health Region for mutations in the gidB gene and its
association with streptomycin resistance.
Materials and Methods
Clinical isolates
Two sets of isolates were analyzed in the present study, the
ﬁrst comprised a total of 82 M. tuberculosis isolates, 52
streptomycin-resistant isolates and 30 that were streptomycin
susceptible (14 multidrug resistant and 16 susceptible to all
ﬁrst-line antibiotics), recovered from the same number of
patients between 2004 and 2006. For this set of isolates, only
DNA was available. All isolates were collected from hospitals
and public health laboratories in the Lisbon Health Region and
ﬁrst-line drug susceptibility testing was carried out as
described previously [3]. The subset of 18 isolates initially
screened in this study comprised the following isolates: BK26,
BK30, BK81, BK87, BK103, BK105, BK120, BK125, BK127,
BK128, BK130, BK178, BK186, BK232, BK272, BK293, BK341
and BK353.
The second set of isolates comprised six isolates, three
streptomycin-resistant isolates and three that were strepto-
mycin susceptible, also from hospitals and public health
laboratories in the Lisbon Health Region. This set was included
in the study to provide data on streptomycin semi-quantitative
drug susceptibility testing (qDST), in particular for Q1 strains.
Streptomycin susceptibility testing
All isolates were tested for streptomycin susceptibility by the
ﬂuorimetric BACTECTM MGITTM 960 system (Becton Dick-
inson Diagnostic Systems, Sparks, MD, USA) using a critical
streptomycin concentration of 1.0 mg/L, according to the
manufacturer’s instructions.
Streptomycin qDST was carried out for the selected
isolates using three streptomycin concentrations (1.0, 4.0
and 20.0 mg/L) with the MGIT 960 system and the Epicenter
V5.80A software equipped with the TB eXIST module (Becton
Dickinson Diagnostic Systems) as previously described [16].
PCR ampliﬁcation and DNA sequencing
The entire open reading frame (ORF) of gidB, plus 96
nucleotides upstream and 56 nucleotides downstream, was
ampliﬁed by PCR, resulting in an 828 bp fragment using
forward oligonucleotide primer gidBF1 and reverse oligonu-
cleotide primer gidbR1 (Table 1). Cycling conditions for this
ampliﬁcation consisted of an initial denaturation step at 94°C
for 10 min, 40 cycles of a denaturation step at 94°C for 1 min,
a primer annealing step at 67.5°C for 35 s and an extension
step at 72°C for 1 min; a ﬁnal extension step at 72°C for
10 min was performed.
The entire rpsL ORF, plus 46 nucleotides upstream and 86
nucleotides downstream, was also ampliﬁed by PCR, resulting
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in a 504 bp fragment using forward oligonucleotide primer
RPSL-1 and reverse oligonucleotide primer RPSL-2 (Table 1)
[17]. Cycling conditions for this ampliﬁcation consisted of 40
cycles of a denaturation step at 94°C for 1 min, a primer
annealing step at 57°C for 2 min and an extension step at 72°C
for 2 min.
The region between nucleotides 10–1037 of the rrs gene
was ampliﬁed by PCR using forward oligonucleotide primer
RRS-1 and reverse oligonucleotide primer RRS-2 (Table 1)
[17]. Cycling conditions consisted of 40 cycles of a denatur-
ation step at 94°C for 1 min, a primer annealing step at 60°C
for 2 min and an extension step at 72°C for 2 min.
All PCR reactions were carried out using approximately
50 ng of template DNA, 10 pmol of each oligonucleotide, a
ﬁnal concentration of 1.5 mM of MgCl2, 0.2 mM of dNTPs and
0.2 U of AmpliTaqTM DNA Polymerase (Applied Biosystems,
Foster City, CA, USA) in a T3 Thermocycler (Biometra,
Goettingen, Germany). Newly described primers were
designed based on the M. tuberculosis H37Rv genome (Gen-
Bank accession no. AL123456.3).
Amplicons were puriﬁed with Wizard SV Gel and the PCR
Clean-Up System (Promega, Madison, WI, USA) prior to
sequencing. Sequencing reactions were performed with the
BigDye Terminator Cycle Sequencing Kit with AmpliTaqTM
DNA polymerase (Applied Biosystems) using oligonucleotide
primers: RPSL-1 for rpsL amplicons, RRS-1 and RRS-2 for rrs
amplicons and gidBF1 and gidBR1 for gidB amplicons (Table 1).
Cycle conditions consisted of an initial denaturation step of 30
s at 96°C followed by 25 cycles of 10 s at 96°C, 5 s at 50°C
and 4 min at 60°C.
Sequence data were aligned with the respective wild-type
alleles from M. tuberculosis H37Rv (GenBank accession no.
AL123456.2), using the CLC Sequence Viewer (CLC Bio,
Aarhus, Denmark) and analysed using BioEdit (v.7.0.5.2, T.A.
Hall).
PCR-RFLP analysis
Mutation A128G in rpsL was detected by MboII (New England
Biolabs, Ipswich, MA, USA) digestion of the rpsL amplicon. Two
micrograms of PCR product were digested with 5 U of MboII
according to the manufacturer’s instructions for 1 h at 37°C.
Absence of restriction indicates the presence of mutation
A128G.
Mutation G238C in gidB was detected as above using the
BsrDI enzyme (New England Biolabs). Two micrograms of PCR
product were digested with 1U of BsrDI according to the
manufacturer’s instructions for 1 h at 37°C. The occurrence of
restriction indicates the presence of mutation G238C, yielding
two fragments (501 + 329 bp).
MIRU-VNTR genotyping
All isolates were genotyped by 12-loci mycobacterial inter-
spersed repetitive unit – variable number of tandem repeats
(MIRU-VNTR) as described by Supply et al. [18]. A dendro-
gram was constructed with the MIRU-VNTRplus web applica-
tion (available at http://www.miru-vntrplus.org) using the Dsw
measure of genetic distance and the unweighted group method
with arithmetic average (UPGMA). A cluster was deﬁned as a
group of more than one isolate sharing the same MIRU-VNTR
proﬁle.
Results
Screening a set of 18 streptomycin-resistant isolates for gidB
mutations we have found four different missense mutations:
F12L, L16R, A80P and S100F. Mutations L16R and S100F were
present in all isolates tested. When analysing the gidB
homologous genes from both M. tuberculosis CDC1551 and
F11 we found mutation S100F to be present on both strains
and that M. tuberculosis F11 also had the L16R mutation.
These two mutations were therefore considered natural
polymorphisms and were not considered as mutations
associated with streptomycin resistance. GidB A80P and
F12L mutations were detected in four isolates and one isolate,
respectively.
The A80P mutation was therefore considered the most
prevalent mutation occurring in the gidB gene and a method to
rapidly screen for G238C (A80P) mutation in gidB through
PCR-RFLP was devised through amplicon digestion with BsrDI.
Thirty-four additional streptomycin-resistant isolates and 30
streptomycin-susceptible isolates were characterized in this
manner. The results obtained for each isolate were compared
with the characterization of the rpsL gene.
Overall, the GidB A80P mutation was detected in 19 out of
82 isolates, eight streptomycin-resistant isolates and 11 that
were streptomycin susceptible. Only MDR isolates were found
to bear the A80P mutation, whereas the 16 pansusceptible
isolates included in the study did not harbour this mutation
(Fig. 1). Also noteworthy, we have sequenced the rpsL and rrs
TABLE 1. Oligonucleotides used for ampliﬁcation and
sequencing of the rpsL and gidB genes
Sequence
Tm
(°C) Reference
RPSL-1 5′-GGCCGACAAACAGAACGT-3′ 63.8 Kirschner et al. [17]
RPSL-2 5′-GTTCACCAACTGGGTGAC-3′ 58.8 Kirschner et al. [17]
RRS-1 5′-GAGAGTTTGATCCTGGCT-3′ 62.9 Kirschner et al. [17]
RRS-2 5′-TGCACACAGGCCACAAGG-3′ 72.5 Kirschner et al. [17]
gidBF1 5′-AAGCGATGCGTGGCCGAGCG-3′ 69.4 This study
gidBR1 5′-CTGGCCCGACCTTACGAGCG-3′ 68.4 This study
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genes of all strains containing the GidB A80P and all lacked
mutations in both genes.
To examine the distribution of this prevalent mutation and
in an attempt to associate this speciﬁc mutation with any
genetic cluster, family or clade, all isolates were genotyped by
12-loci MIRU-VNTR. We found that all isolates carrying the
GidB A80P mutation belonged to genetic cluster Q1 (Fig. 1).
The occurrence of the GidB A80P mutation in all Q1 isolates
and the fact that this mutation occurs among both strepto-
mycin-resistant and susceptible isolates may suggest that this
mutation has no contribution to streptomycin resistance but
may rather be, from a resistance standpoint, a neutral
phylogenetic polymorphism characteristic of Q1 isolates.
Alternatively, this mutation might constitute an adaptation
mechanism acquired by an ancestral Q1 isolate that yielded
clinically signiﬁcant but borderline streptomycin resistance on
the standard MGIT drug susceptibility test.
To further elucidate the contribution of the GidB A80P
mutation to streptomycin resistance, we decided to study the
streptomycin qDST proﬁles in a second set of six M. tubercu-
losis clinical isolates composed of four Q1 isolates carrying the
GidB A80P mutation, one Beijing strain carrying the rpsL K43R
mutation and a pansusceptible isolate with no mutation in gidB,
rpsL or rrs. The results obtained show that the four Q1 isolates
were all resistant to 1 mg/L, and three of themwere resistant to
4 mg/L, while the remaining isolate displayed an intermediate
0.1
BK103 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK104 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK105 IRSEP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK1151 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK120 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK125 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK127 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK128 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK130 IRSEP2005 2 2 1 2 1 2 6 1 5 2 3 2
BK149 IRS2006 2 2 1 2 1 2 6 1 4 2 3 2
BK1519 IRSEP2005 2 2 4 2 2 2 5 1 5 2 3 2
BK178 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK186 IRSEP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK193 IRP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK215 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK232 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK239 IRP2005 2 2 3 4 3 2 5 1 5 2 3 2
BK248 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK26 IRS2005 2 2 1 2 1 2 4 1 4 2 3 2
BK260 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK269 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK272 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK293 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK296 IRP2006 2 2 1 2 1 2 4 1 4 2 3 2
BK297 IRE2006 1 2 3 3 2 2 6 1 4 2 2 2
BK30 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK305 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK309 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK325 IRSP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK341 IRSP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK342 IREP2006 2 2 1 2 1 2 4 1 4 2 3 2
BK350 IREP2006 2 2 1 2 1 2 4 1 4 2 3 2
BK353 IRSE2005 2 2 1 3 1 2 6 1 5 2 2 2
BK372 IR2005 2 2 1 2 1 2 4 1 4 2 3 2
BK373 IRSE2005 2 2 1 2 1 2 6 1 4 2 3 2
BK408 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK460 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK463 IRS2005 2 2 1 2 1 2 6 1 4 2 3 2
BK509 IRSEP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK516 IRSP2005 2 2 4 2 2 2 5 1 5 2 3 2
BK519 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK525 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK585 IRSEP2006 2 2 1 2 1 2 4 1 4 2 3 2
BK624 IR2006 2 2 5 3 2 1 6 1 4 2 2 2
BK633 IRSEP2006 2 2 1 2 1 2 4 1 4 2 3 2
BK643 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK667 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK702 IRSE2006 2 2 1 2 1 2 6 1 4 2 3 2
BK733 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK801 IRSE2005 2 2 1 2 1 2 6 1 4 2 3 2
BK81 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK840 IREP2005 2 2 1 2 1 2 4 1 4 2 3 2
BK849 IRSEP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK87 IRS2005 2 2 1 2 1 2 6 1 4 2 3 2
BK882 IRSP2005 2 2 1 2 1 2 6 1 4 2 3 2
BK94 IRSP2006 2 2 1 2 1 2 6 1 4 2 3 2
BK971 IRSEP2006 2 2 2 2 3 2 5 1 5 2 2 2
HMT58 S2004 2 2 2 5 2 2 5 1 5 3 3 3
HPV108 Pansusceptible2006 2 2 3 4 2 2 5 1 5 3 3 2
HPV109 Pansusceptible2006 1 2 4 2 2 2 3 1 5 3 3 2
HPV117 Pansusceptible2006 2 2 3 8 2 2 5 1 6 3 5 2
HPV119 Pansusceptible2006 2 5 5 5 2 2 5 1 8 4 2 2
HPV139 Pansusceptible2006 2 2 1 3 2 2 5 1 5 3 2 2
HPV154 Pansusceptible2006 2 2 3 4 2 2 5 1 7 2 5 2
HPV17 S2004 2 2 2 3 2 2 5 1 4 3 3 2
HPV170 Pansusceptible2006 2 2 1 2 1 2 6 1 4 3 3 2
HPV171 S2004 2 2 4 3 2 2 5 1 5 3 3 2
HPV186 Pansusceptible2006 2 2 1 3 2 2 5 1 6 3 2 2
HPV192 Pansusceptible2006 1 2 6 3 2 2 6 2 5 2 3 2
HPV195 Pansusceptible2006 3 3 4 3 3 2 5 1 6 3 3 2
HPV197 Pansusceptible2006 2 2 3 3 3 3 5 1 6 4 5 3
HPV198 S2004 2 2 1 4 1 2 4 2 5 3 4 2
HPV203 Pansusceptible2006 1 2 4 3 2 2 6 1 5 2 2 2
HPV268 IRSEP2004 2 2 1 2 1 2 4 1 4 2 3 2
HPV41 S2004 2 2 4 3 2 2 5 1 5 3 3 2
HPV44 S2004 2 2 3 3 2 2 5 1 4 3 3 2
HPV50 Pansusceptible2006 2 2 1 3 1 2 5 1 6 2 2 2
HPV53 S2004 2 2 4 3 2 2 5 1 5 2 3 2
HPV53 Pansusceptible2006 2 2 1 3 1 2 6 1 5 3 2 2
HPV55 Pansusceptible2006 2 2 1 2 1 2 6 1 4 2 2 2
HPV59 IRSEP2005 2 2 1 2 1 2 4 1 4 2 3 2
HPV94 Pansusceptible2006 2 2 5 3 3 1 6 1 4 2 2 2
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FIG. 1. MIRU-VNTR dendrogram of the 82 M. tuberculosis clinical isolates screened for gidB and rpsL mutations, including the 18 isolates initially
screened by sequencing analysis (ﬁlled circles). Isolates carrying the GidB A80P mutation are shown in bold. Resistance proﬁle: I, isoniazid; R,
rifampicin; S, streptomycin; E, ethambutol; P, pyrazinamide.
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resistance to 4 mg/L (Table 2). All Q1 isolates were susceptible
to 20 mg/L. The Beijing strain with the K43R mutation on the
rpsL gene was resistant to the three tested streptomycin
concentrations whereas the pansusceptible clinical strain and
the control strain H37Rv were found to be susceptible to the
three tested concentrations (Table 2). The results obtained
show that the Q1 isolates carrying the GidB A80P mutation
display an increased streptomycin resistance-level towards an
intermediate-level resistance (Table 2). Three Q1 isolates with
the GidB A80Pmutation (two streptomycin susceptible and one
resistant) were also blindly retested in duplicate, using standard
DST methodology on BACTEC 960 MGIT with a streptomycin
breakpoint of 1 mg/L. Surprisingly, the two isolates (IHMT308
and 361) initially considered as streptomycin susceptible were
considered resistant upon retesting (Table 2).
Discussion
In the present study, we have analysed the gidB gene, encoding
an rRNA methyltransferase, in streptomycin-resistant and
susceptible isolates. Methyltransferases have demonstrated a
growing importance in the action mechanism of and resistance
pathways to several antimicrobial agents in M. tuberculosis.
Intrinsic resistance to macrolides is thought to be associated
with 23S rRNA methyltransferases encoded by the erm genes
whereas loss of TlyA methyltransferase confers resistance to
cyclic peptides (e.g. capreomycin). However, most rRNA
methyltransferases are still unknown in M. tuberculosis [19].
The screening of gidB mutations revealed that besides two
naturally occurring polymorphisms (L16R and S100F), two
different missense mutations were found, F12L and A80P, the
latter being the most prevalent. Both mutations had never
been described before and were only detected in isolates
without rpsL and rrs mutations. As a result, gidB mutations may
account for streptomycin resistance in isolates with both wild-
type rpsL and rrs. Nevertheless, the A80P mutation was
detected in MDR isolates susceptible to streptomycin but not
in pansusceptible isolates.
The A80P mutation has not, to our knowledge, been
previously described and bioinformatic analysis revealed that
this mutation occurs in the alpha-helix D close to the S-
adenosyl-L-methionine binding consensus sequence, according
to homology analysis with E. coli GidB and respective crystal
structure [20]. Moreover, this substitution does not appear to
be chemically conservative and may eventually hamper the
functionality of GidB in methylating the 16S rRNA, leading to
an increase in the streptomycin resistance level [13].
Other studies have reported the occurrence of gidB
mutations in susceptible isolates and this phenomenon appears
to be related to streptomycin low-level resistance [21,22].
Streptomycin qDST revealed that the majority of tested strains
carrying the A80P mutation exhibit an intermediate strepto-
mycin resistance level (i.e. either resistant or intermediate
resistance to 4 mg/L but susceptible to 20 mg/L), which may
correlate with the streptomycin low-level resistance reported
by others relative to other gidB mutations in M. tuberculosis
clinical isolates [14,23]. It is possible that strains carrying this
mutation may occasionally yield inconsistent DST results as
demonstrated by the streptomycin retesting of selected
isolates. In the present study the use of the novel qDST
methodology takes into account the growth rate in both drug-
containing and drug-free media to establish intermediate
resistance levels relative to a speciﬁc concentration, rather
than just resistant or susceptible as in the traditional MGIT
methodology [16]. Although the present study could beneﬁt
from having a larger sample of isolates subjected to the qDST
assay, the fact that all four Q1 isolates showed a consistent
resistance at 4 mg/L demonstrates that these results are
representative of Q1 strains.
Our results indicate that a mutation in gidB may be enough
to confer clinically relevant streptomycin resistance, although
TABLE 2. Streptomycin qDST for selected strains carrying the GidB A80P mutation
Isolate Year
First-line
resistancea
MIRU-VNTR
clusterb
Mutationsc Streptomycin qDSTd
Streptomycin
DST reteste
gidB rpsL rrs 1 mg/L 4 mg/L 20 mg/L #1 #2
H37Rv - Pansusceptible N.C. None None None S S S nd nd
HPV65 2008 Pansusceptible N.C. None None None S S S nd nd
IHMT295 2008 IRSEP N.C. (Beijing) None K43R None R R R nd nd
HPV115 2008 IRSEP Q1 G238C (A80P) none None R R S nd nd
IHMT308 2008 IRP Q1 G238C (A80P) None None R R S R R
IHMT361 2008 IREP Q1 G238C (A80P) None None R I S R R
IHMT149 2009 IRSEP Q1 G238C (A80P) None None R R S R R
aFirst-line resistance: I, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol; P, pyrazinamide.
bN.C., non-clustered.
cFor these isolates the respective genes have been sequenced as described in the Material and Methods section. S100F and L16R mutations in gidB are omitted.
dStreptomycin qDST: S, susceptible; I, intermediate; R, resistant.
eStreptomycin DST retest: R, resistant; S, susceptible; nd, not determined.
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we do not discard a possible contribution of efﬂux mechanisms
to the overall streptomycin resistance level, as proposed by
Spies et al. [24] when studying the synergistic effect between
gidB mutations and efﬂux pump inhibitors.
The association of the GidB A80P mutation with the genetic
cluster Q1, a highly prevalent cluster of M/XDR-TB isolates in
Lisbon, Portugal, is important because it allows the use of this
mutation as a surrogate marker for Q1 isolates and can be
useful for its detection. The occurrence of the A80P mutation
in MDR isolates is therefore only linked with the high
association of the Q1 cluster with MDR, as fully susceptible
Q1 isolates have never been found and described. The
detection of these isolates may be useful in managing M/
XDR-TB in the region because early detection of Q1 isolates
would prove valuable for the design of adequate treatment
regimens and patient isolation [3–5].
Other mutations may be useful for assignment to M. tuber-
culosis lineages. For example, the L16R substitution is associ-
ated with isolates of Latin American Mediterranean (LAM)
lineage, which include the M. tuberculosis F11 strain [21,23]. In
fact, approximately 50% of the strains circulating in the Lisbon
Health Region belong to the LAM lineage, of which 1.67%
represent Q1 isolates belonging to the LAM4 sub-lineage (J.
Perdiga˜o, I. Portugal, unpublished data) [25]. The phylogenetic
association of the GidB S100F polymorphism is, however,
unclear as it was present in all the 18 isolates in which the gidB
gene has been fully sequenced. Data from Ioerger et al. [26]
and from the updated version of M. tuberculosis H37Rv
(Genbank accession no. AL123456.3) conﬁrm that this muta-
tion is due to a sequencing error present in the previous
release (Genbank accession no. AL123456.2).
Given the high resistance rates in this and other settings, the
correct assessment of streptomycin resistance level and
eventual association with a molecular marker can be useful
in the decision of whether streptomycin should be used in
some therapeutic regimens.
Nevertheless, it is also important to stress that the
addition of streptomycin alone to a treatment regimen, such
as the former WHO-recommended Category II regimen, is
counterproductive as it may lead to the acquisition of
streptomycin resistance and ampliﬁcation of resistance to
other drugs in use [2,27]. A recently published study
performed in Peru by Ponce et al. [28] showed that the cure
rate was lower for the WHO Category II regimen compared
with the Category I regimen. According to the authors, this
should support the phasing-out of the WHO Category II
regimen. Additional data from other countries seem to also
support this notion [29,30].
In conclusion, our results suggest that the cluster-speciﬁc
gidB polymorphism A80P is responsible for an intermediate
level of streptomycin resistance, which has implications for
routine streptomycin DST testing as currently performed
using a single critical concentration, streptomycin prescription
and M/XDR-TB detection. Our data further contribute to
global awareness of the role of gidB mutations in the process of
streptomycin resistance development.
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